— “Drug companies’ refusal to invest in research [of Ebola] and the conditions on the ground created by neoliberal policies that exacerbate and even encourage outbreaks goes unmentioned. […] Ebola is a problem that is not being solved because there is almost no money to be made in solving it. It’s an unprofitable disease” (Leigh Phillips,“The Political Economy of Ebola”, Jacobin)

— “When pharmaceutical companies are deciding where to direct their R. & D. money, they naturally assess the potential market for a drug candidate. That means that they have an incentive to target diseases that affect wealthier people (above all, people in the developed world), who can afford to pay a lot. They have an incentive to make drugs that many people will take. And they have an incentive to make drugs that people will take regularly for a long time—drugs like statins.” (James Surowiecki, “Ebolanomics”, The New Yorker)